osimertinib
astrazeneca
['adaura', 'lung', 'osimertinib']
 mature data on use of adjuvant osimertinib in egfr mutant lung cancer (adaura)
dfs benefit maintained (median dfs 65.8 vs. 21.9 months; hr 0.27). benefit across all stages. great news for patients with resected stage ib-iiia egfr mutant lung ca #esmo2022 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18 #SE15